KILR® Cytotoxicity CD16 Effector Cells

Driving Robust and Reproducible ADCC and T-Cell Redirection

Effector cells such as peripheral blood mononuclear cells (PBMCs) have inherent donor variability, reducing consistency and reproducibility in lot release assays. Antibody-Dependent Cell Cytotoxicity (ADCC) assays that measure cell death often have low signal-to-background (S/B) ratios and suffer from this donor variability of the PBMCs.

Eurofins DiscoverX® offers KILR CD16 Effector Cells are single donor-derived human primary cells. They are ideal for measuring target cell death using ADCC or bi-specific antibody-mediated T-cell redirection (TCR) for screening, characterization, and QC lot release of immunotherapeutics (antibody drugs). These effector cells ensure assay reproducibility with higher S/B ratios, eliminating donor variability.

Product Highlights
  • Eliminate Donor Variability – Primary effector cells (human cytotoxic T lymphocytes) from a single donor engineered to stably express CD16 (V158)
  • Fit for Long-Term QC Testing – Uniformly manufactured to ensure lot-to-lot consistency and produce high S/B ratios
  • Measure Target Cell Death – High killing capacity for implementing ADCC or TCR for lot release or characterization

Consider Eurofins DiscoverX’s custom development capabilities for custom cell lines, assays, & enzyme development.

SHOP PRODUCTSIMMUNOTHER. EBOOKDOWNLOAD APPNOTE

Highlights

Single Donor-Derived Effector Cells

SafeValue must use [property]=binding: Single Donor-Derived Effector Cells (see https://angular.dev/best-practices/security#preventing-cross-site-scripting-xss)

Single donor-derived cytotoxic T lymphocytes (CTLs) transfected with CD16 (FcγRIIIa-V158). KILR CD16 Effector Cells are engineered to express CD16 receptor to form an immunological synapse between the target antibody and antigen that ultimately triggers the release of perforins, granzymes, and cytokines that promote cell death when delivered to target cell cytosol. A. KILR CD16 Effector Cells showing a polyclonal population of predominantly (>98%) CD8+ cells and (B.) positive for CD3 with robust and stable expression of CD16. C. KILR CD16 Effector Cells have functional CD3 as demonstrated by the ability of cells to stimulate T-cell redirection in the presence of blinatumomab (see the section on T-cell redirection).

Excellent Intermediate Precision of ADCC and High Lot-to-Lot Reproducibility

SafeValue must use [property]=binding: Excellent Intermediate Precision of ADCC and High Lot-to-Lot Reproducibility (see https://angular.dev/best-practices/security#preventing-cross-site-scripting-xss)

Evaluation of the intra- and inter-lot performance of KILR CD16 Effector Cells in a Rituximab ADCC model. High lot-to-lot reproducibility ensures long-term support for QC testing.